Active Biotech to Present at the Rodman & Renshaw 12th Annual Healthcare Conference
Lund, Sweden, September 9, 2010 - Active Biotech (NASDAQ OMX Nordic: ACTI) is
scheduled to present at the Rodman & Renshaw 12th Annual Healthcare Conference
on Tuesday, September 14 at the New York Palace Hotel in New York City, US.
During the presentation, an update regarding Active Biotech's development
programs will be provided.
The presentation will include projects in or entering Phase III; laquinimod, a
novel oral immunomodulatory drug for the treatment of multiple sclerosis,
licensed to Teva Pharmaceutical Industries Ltd, the prostate cancer project TASQ
and ANYARA, Active Biotech's novel concept for tumor therapy in a Phase III
study for renal cell cancer. Also, the project 57-57 and the pre-clinical ISI
project will be presented.
The audio and slide presentation will be webcasted live and can be accessed via
the Active Biotech web site. To access the live and replay presentations please
go to - www.activebiotech.com
The presentation will take place on September 14, at 2:25 pm US Eastern Daylight
Time / 20:25 Central European Summer Time.
About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. Projects in or entering
pivotal phase are laquinimod, an orally administered small molecule with unique
immunomodulatory properties for the treatment of multiple sclerosis, TASQ for
prostate cancer as well as ANYARA for use in cancer targeted therapy, primarily
of renal cell cancer. In addition, laquinimod is in Phase II development for
Crohn's and Lupus. Further projects in clinical development comprise the two
orally administered compounds, 57-57 for SLE & Systemic Sclerosis and RhuDex(TM)
for RA. Please visit www.activebiotech.comfor more information.
Active Biotech is required under the Securities Markets Act to make the
information in this press release public. The information was submitted for
publication at 08:30 a.m. CEST on September 9, 2010.
Active Biotech AB
Göran Forsberg, VP Investor Relations & Business Development
P.O. Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00
Active Biotech to present at the Rodman & Renshaw 12th Annual Healthcare Conference:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Active Biotech via Thomson Reuters ONE